Clinical Trial Update: MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This update reports a Phase 1 trial of MSX-122 administered orally in patients with refractory metastatic or locally advanced solid tumors, with the study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• MSX-122

Snippet

Sponsor: Metastatix, Inc. | Conditions: Solid Tumors | Phase 1 | Status: SUSPENDED